| Drug Type Small molecule drug | 
| Synonyms- | 
| Target | 
| Action antagonists | 
| Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| RegulationSpecial Review Project (China) | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Phase 1 | United States  | 30 Jan 2022 | |
| Malignant Solid Neoplasm | IND Approval | China  | 02 Jun 2011 | |
| Breast Cancer | IND Application | China  | 12 Dec 2016 | |
| Colorectal Cancer | IND Application | China  | 12 Dec 2016 | |
| Non-Small Cell Lung Cancer | IND Application | China  | 12 Dec 2016 | |
| Stomach Cancer | IND Application | China  | 12 Dec 2016 | 





